Spatial distribution of intraperitoneally administrated paclitaxel nanoparticles solubilized with poly (2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) in peritoneal metastatic nodules

Cancer Science

Volumn 102, Issue 1, 2011, Pages 200-205

  Kamei, Takao ^a   Kitayama, Joji ^a   Yamaguchi, Hironori ^a   Soma, Daisuke ^a   Emoto, Shigenobu ^a   Konno, Tomohiro ^b   Ishihara, Kazuhiko ^b   Ishigami, Hironori ^a   Kaisaki, Shoichi ^a   Nagawa, Hirokazu ^a  

^a THE UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COPOLYMER; FLUORESCEIN; NANOPARTICLE; PACLITAXEL; POLY(2 METHACRYLOXYETHYL PHOSPHORYLCHOLINE CO N BUTYLMETHACRYLATE); PTX 30W; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INFILTRATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; FEMALE; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; LIVER; MOUSE; NANOPHARMACEUTICS; NONHUMAN; PERITONEUM METASTASIS; PRIORITY JOURNAL; SOLUBILIZATION; STOMACH CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; LIVER; METHACRYLATES; MICE; MICE, INBRED BALB C; NANOPARTICLES; PACLITAXEL; PERITONEAL NEOPLASMS; PHOSPHORYLCHOLINE; SOLUBILITY; TISSUE DISTRIBUTION;

EID: 78650226437     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01747.x     Document Type: Article

References (33)

1. D'Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004; 240: 808-16.
2. Legge F, Petrillo M, Adamo V, Pisconti S, Scambia G, Ferrandina G. Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcome. BMC Cancer 2008; 8: 367.
3. Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Cancer Treat Res 1996; 82: 53-63.
4. Eiseman JL, Eddington ND, Leslie J et al. Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Pharmacol 1994; 34: 465-71.
5. Gelderblom H, Verweij J, van Zomeren DM et al. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. Clin Cancer Res 2002; 8: 1237-41.
6. Ishigami H, Kitayama J, Kaisaki S et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol 2010; 21: 67-70.
7. Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34-43.
8. Markman M, Bundy BN, Alberts DS et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19: 1001-7.
9. de Bree E, Rosing H, Michalakis J et al. Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination. Eur J Surg Oncol 2006; 32: 666-70.
10. Ishihara K, Iwasaki Y, Nakabayashi N. Polymeric lipid nanosphere consisting of water-soluble poly(2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate). Polym J 1999; 31: 1231-6.
11. Goda T, Goto Y, Ishihara K. Cell-penetrating macromolecules: direct penetration of amphipathic phospholipid polymers across plasma membrane of living cells. Biomaterials 2010; 31: 2380-7.
12. Konno T, Watanabe J, Ishihara K. Enhanced solubility of paclitaxel using water-soluble and biocompatible 2-methacryloyloxyethyl phosphorylcholine polymers. J Biomed Mater Res A 2003; 65: 209-14.
13. Soma D, Kitayama J, Konno T et al. Intraperitoneal administration of paclitaxel solubilized with poly(2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) for peritoneal dissemination of gastric cancer. Cancer Sci 2009; 100: 1979-85.
14. Kimura M, Konno T, Miyamoto Y, Kojima Y, Maeda H. Intracavitary administration: pharmacokinetic advantages of macromolecular anticancer agents against peritoneal and pleural carcinomatoses. Anticancer Res 1998; 18: 2547-50.
15. Sako A, Kitayama J, Koyama H et al. Transduction of soluble Flt-1 gene to peritoneal mesothelial cells can effectively suppress peritoneal metastasis of gastric cancer. Cancer Res 2004; 64: 3624-8.
16. Ishihara K, Ueda T, Nakabayashi N. Preparation of phospholipid polymers and their properties as polymer hydrogel membrane. Polym J 1990; 22: 355-60.
17. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387-92.
18. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65: 271-84.
19. Vicent MJ, Duncan R. Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol 2006; 24: 39-47.
20. Gradishar WJ, Tjulandin S, Davidson N et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23: 7794-803.
21. Hamaguchi T, Matsumura Y, Suzuki M et al. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer 2005; 92: 1240-6.
22. Rizvi NA, Riely GJ, Azzoli CG et al. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol 2008; 26: 639-43.
23. Lankelma J, Dekker H, Luque FR et al. Doxorubicin gradients in human breast cancer. Clin Cancer Res 1999; 5: 1703-7.
24. Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 2005; 11: 8782-8.
25. Los G, Mutsaers PH, van der Vijgh WJ, Baldew GS, de Graaf PW, McVie JG. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 1989; 49: 3380-4.
26. Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 2002; 8: 878-84.
27. Kyle AH, Huxham LA, Yeoman DM, Minchinton AI. Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors. Clin Cancer Res 2007; 13: 2804-10.
28. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006; 6: 583-92.
29. Yashiro M, Chung YS, Nishimura S, Inoue T, Sowa M. Fibrosis in the peritoneum induced by scirrhous gastric cancer cells may act as "soil" for peritoneal dissemination. Cancer 1996; 77: 1668-75.
30. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994; 271: 58-65.
31. Kuh HJ, Jang SH, Wientjes MG, Weaver JR, Au JL. Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther 1999; 290: 871-80.
32. Carney ME, Lancaster JM, Ford C, Tsodikov A, Wiggins CL. A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not? Gynecol Oncol 2002; 84: 36-42.
33. Bristow RE, Zahurak ML, del Carmen MG et al. Ovarian cancer surgery in Maryland: volume-based access to care. Gynecol Oncol 2004; 93: 353-60.